Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
River Eletec
6666
Fit Easy
212A
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 9.59%444.23B | 7.17%1.85T | 17.18%620.22B | 5.30%459.73B | -11.09%364B | 15.70%405.34B | 14.97%1.73T | 14.51%529.28B | 22.07%436.58B | 25.79%409.4B |
Cost of revenue | 5.77%358.81B | 10.44%1.54T | 12.77%498.75B | 8.35%357.37B | 4.59%341.68B | 15.80%339.25B | 11.56%1.39T | 11.02%442.29B | 15.28%329.85B | 20.15%326.68B |
Gross profit | 29.24%85.42B | -6.47%312.24B | 39.63%121.47B | -4.11%102.35B | -73.01%22.32B | 15.20%66.09B | 31.81%333.82B | 36.36%86.99B | 49.23%106.74B | 54.42%82.72B |
Operating expense | 19.97%74.3B | 8.88%277.39B | -4.34%81.22B | 14.69%68.37B | 15.86%65.87B | 15.96%61.93B | 22.21%254.78B | 34.88%84.9B | 14.07%59.62B | 17.21%56.85B |
Selling and administrative expenses | 18.43%73.84B | 9.41%276.04B | -4.38%79.85B | 15.28%67.96B | 17.06%65.89B | 16.40%62.35B | 19.50%252.31B | 33.07%83.5B | 12.32%58.95B | 15.33%56.29B |
-General and administrative expense | 18.43%73.84B | 9.41%276.04B | -4.38%79.85B | 15.28%67.96B | 17.06%65.89B | 16.40%62.35B | 19.50%252.31B | 33.07%83.5B | 12.32%58.95B | 15.33%56.29B |
Other operating expenses | 84.42%1.44B | -3.65%7.05B | -0.29%3.42B | 31.74%1.37B | 7.04%1.48B | -46.63%783M | 76.51%7.32B | 162.23%3.43B | --1.04B | -38.21%1.38B |
Total other operating income | -18.29%983M | 17.61%5.7B | 0.84%2.05B | 153.30%960M | 83.62%1.49B | -25.97%1.2B | -28.62%4.85B | 82.57%2.03B | 69.96%379M | -67.89%812M |
Operating profit | 167.15%11.12B | -55.92%34.84B | 1,824.04%40.25B | -27.89%33.98B | -268.36%-43.55B | 5.02%4.16B | 76.52%79.04B | 145.54%2.09B | 144.62%47.12B | 410.88%25.87B |
Net non-operating interest income (expenses) | 89.90%8.95B | -18.45%-14.22B | 237.03%4.45B | -22.89%-17.05B | -607.25%-6.34B | -21.61%4.71B | -345.49%-12.01B | -354.03%-3.25B | -1,150.86%-13.87B | 34.98%-896M |
Non-operating interest income | 74.46%13.71B | 32.69%3.04B | 0.54%933M | ---- | ---- | 4.62%7.86B | -10.37%2.29B | -41.56%928M | ---- | 265.45%1.1B |
Non-operating interest expense | 51.34%4.76B | 20.73%17.26B | -184.25%-3.52B | 22.89%17.05B | 217.48%6.34B | 109.73%3.15B | 172.27%14.3B | 1,251.78%4.18B | 939.10%13.87B | 18.88%2B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -4.50%5.82B | 242.73%11.36B | 938.97%5.21B | -113.34%-391M | 20.49%447M | 865.61%6.09B | 123.00%3.31B | -180.75%-621M | 135.94%2.93B | 106.21%371M |
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 72.96%25.89B | -54.54%31.98B | 2,907.14%49.91B | -54.28%16.54B | -295.09%-49.44B | 41.12%14.97B | 154.24%70.35B | -161.33%-1.78B | 261.91%36.18B | 1,207.08%25.34B |
Income tax | 80.14%9.94B | -68.99%4.67B | 422.21%10.77B | -13.37%5.97B | -362.31%-17.58B | 14.74%5.52B | 17.33%15.06B | -420.94%-3.34B | 30.91%6.89B | 388.48%6.7B |
Net income | 68.75%15.94B | -50.61%27.31B | 2,404.48%39.15B | -63.90%10.57B | -270.92%-31.86B | 63.05%9.45B | 272.67%55.29B | -15.92%1.56B | 518.54%29.29B | 609.12%18.64B |
Net income continuous operations | 68.75%15.94B | -50.61%27.31B | 2,404.48%39.15B | -63.90%10.57B | -270.92%-31.86B | 63.05%9.45B | 272.67%55.29B | -15.92%1.56B | 518.54%29.29B | 609.12%18.64B |
Noncontrolling interests | 58.54%566M | -14.55%1.93B | -72.49%288M | 30.15%708M | 73.57%578M | 6.25%357M | 2.87%2.26B | 122.77%1.05B | -23.16%544M | -42.29%333M |
Net income attributable to the company | 69.16%15.38B | -52.15%25.38B | 7,415.86%38.86B | -65.68%9.87B | -277.20%-32.44B | 66.56%9.09B | 319.60%53.03B | -62.78%517M | 613.73%28.75B | 531.82%18.31B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 69.16%15.38B | -52.15%25.38B | 7,415.86%38.86B | -65.68%9.87B | -277.20%-32.44B | 66.56%9.09B | 319.60%53.03B | -62.78%517M | 613.73%28.75B | 531.82%18.31B |
Gross dividend payment | ||||||||||
Basic earnings per share | 69.14%91.79 | -52.15%151.51 | 7,432.14%231.99 | -65.69%58.9 | -277.18%-193.66 | 66.57%54.27 | 319.32%316.63 | -62.85%3.08 | 613.72%171.65 | 531.85%109.3 |
Diluted earnings per share | 69.14%91.79 | -52.15%151.51 | 7,431.81%231.9797 | -65.69%58.9 | -277.18%-193.66 | 66.57%54.27 | 319.32%316.63 | -62.85%3.08 | 613.72%171.65 | 531.85%109.3 |
Dividend per share | 0 | -44.44%50 | -50.00%30 | 0 | -33.33%20 | 0 | 125.00%90 | 200.00%60 | 0 | 50.00%30 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |